COMMUNIQUÉS West-GlobeNewswire

Eurobio scientific signs definitive agreement to acquire CareDx’s transplant Lab Product division
16/04/2026
EUROBIO SCIENTIFIC SIGNS DEFINITIVE AGREEMENT TO ACQUIRE CAREDX’s TRANSPLANT LAB PRODUCT DIVISION Acquisition of CareDx’s ‘lab products’ portfolio creates new opportunities for growth and innovation in the fast growing [...]
Greywolf Therapeutics appoints Edwin Moses as Chair
16/04/2026
OXFORD, United Kingdom, April 16, 2026 (GLOBE NEWSWIRE) -- Greywolf Therapeutics, a clinical-stage biotech company advancing novel antigen modulation treatments for cancer and autoimmune diseases, has appointed Edwin [...]
TME PHARMA ANNONCE LA PUBLICATION DANS *NATURE COMMUNICATIONS* DES RÉSULTATS DE L'ESSAI GLORIA CONCERNANT LE VOLET D'EXTENSION A DE PHASE 1/2 DE LA « TRIPLE THÉRAPIE » NOX-A12
16/04/2026
TME PHARMA ANNONCE LA PUBLICATION DANS *NATURE COMMUNICATIONS* DES RÉSULTATS DE L'ESSAI GLORIA CONCERNANT LE VOLET D'EXTENSION A DE PHASE 1/2 DE LA « TRIPLE THÉRAPIE » NOX-A12 Berlin, Allemagne, le 16 avril 2026, 8 h 00 [...]
Bavarian Nordic Receives Swissmedic Approval for Chikungunya Vaccine
16/04/2026
COPENHAGEN, Denmark, April 16, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Swiss Agency for Therapeutic Products, Swissmedic, has approved VIMKUNYA ® (recombinant, adsorbed) for active immunization [...]
Pharming Group announces the 2026 Annual General Meeting of Shareholders
16/04/2026
Leiden, the Netherlands, April 16, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that the Company’s 2026 Annual General Meeting of Shareholders (the “ [...]
Eurobio Scientific signe un accord définitif en vue de l'acquisition de la division « Lab Products » de CareDx dédiée à la transplantation
16/04/2026
EUROBIO SCIENTIFIC SIGNE UN ACCORD DÉFINITIF EN VUE DE L'ACQUISITION DE LA DIVISION « LAB PRODUCTS 1 » DE CAREDX DÉDIÉE À LA TRANSPLANTATION L'acquisition du portefeuille « Lab Products » de CareDx ouvre de nouvelles [...]
TME Pharma Announces Publication of NOX-A12 “Triple Therapy” Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications
16/04/2026
TME Pharma Announces Publication of NOX-A12 “Triple Therapy” Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications Berlin, Germany , April 16, 2026, 08.00am CET – TME Pharma N.V. (Euronext Growth [...]
ONWARD Medical Successfully Raises over EUR 40 Million in Capital Increase
16/04/2026
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE [...]
UroFlow Claims Evaluated: Reviewing the Official Website Benefits & Ingredients to Support Prostate Health
16/04/2026
A 2026 consumer information overview of how UroFlow presents its Saw Palmetto, Pygeum Africanum, Lycopene, and Tomato Sauce Trick ingredient references, official website benefit descriptions, pricing structure, and [...]
Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
15/04/2026
BEDFORD, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter [...]
Teladoc Health to Announce First Quarter 2026 Financial Results
15/04/2026
NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE: TDOC), the global leader in virtual care, announced that it will release first quarter 2026 results on Wednesday, April 29, 2026, after the market [...]
Elion Therapeutics Announces Initiation of Turletricin (EL219) Phase 2 Study in Invasive Mould Infection
15/04/2026
- Turletricin Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA - - Elion to Present Turletricin Clinical Data at ESCMID Global - BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Elion [...]
Vivos Therapeutics Reports Full Year 2025 Financial Results
15/04/2026
Full Year 2025 revenue increased 16% Integration of The Sleep Center of Nevada and shift in business model support path to improved revenues, margins and cash flow Management to Host Conference Call today at 5:00 pm ET [...]
Algernon Health Announces Effective Date of Previously Announced Name Change to “Grey Matters Health Inc.” and its 10:1 Share Consolidation
15/04/2026
VANCOUVER, British Columbia, April 15, 2026 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “ Company ” or “ Algernon ”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces that effective [...]
Running with Purpose: Nashville Podiatrist Dr. Lanier Shares Expert Tips for Injury-Free Half Marathon Training
15/04/2026
NASHVILLE, Tenn., April 15, 2026 (GLOBE NEWSWIRE) -- Dr. Yerusalem Lanier is preparing to take on the Rock ‘n’ Roll Half Marathon on April 25, 2026, for the second year alongside her daughters and husband. For Dr. [...]
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
15/04/2026
WESTLAKE VILLAGE, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology [...]
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026
15/04/2026
SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical [...]
Wave Life Sciences Announces Proposed Redomiciliation to the United States
15/04/2026
CAMBRIDGE, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, [...]
Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
15/04/2026
Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity, Ratutrelvir topline Phase 2a data show a differentiated [...]

Pages